转移性去势抵抗性前列腺癌中针对DNA修复基因缺陷的治疗综述。
A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer.
作者信息
Maslov Diana V, Sember Quinne, Cham Jason, Bhangoo Munveer
机构信息
Department of Hematology/Oncology, Scripps Health System, San Diego, CA, United States.
Scripps Clinic/Green Hospital, Department of Internal Medicine, San Diego, CA, United States.
出版信息
Front Oncol. 2023 Mar 14;13:1150777. doi: 10.3389/fonc.2023.1150777. eCollection 2023.
Prostate cancer is the most common cancer in men. About 6% of those diagnosed will develop metastatic disease. Unfortunately, metastatic prostate cancer is fatal. Prostate cancer can be castration sensitive or castration resistant. Many treatments have been shown to improve progression free survival and overall survival in metastatic castration resistant prostate cancer (mCRPC). In recent years, studies have been exploring targeting mutations in the DNA Damage Repair (DDR) response that may amplify oncogenes. In this paper, we aim to discuss DDR, new approved targeted therapies, and the most recent clinical trials in the setting of metastatic CRPC.
前列腺癌是男性中最常见的癌症。约6%的确诊患者会发展为转移性疾病。不幸的是，转移性前列腺癌是致命的。前列腺癌可以是去势敏感型或去势抵抗型。许多治疗方法已被证明可改善转移性去势抵抗性前列腺癌（mCRPC）的无进展生存期和总生存期。近年来，研究一直在探索针对DNA损伤修复（DDR）反应中的突变，这些突变可能会放大致癌基因。在本文中，我们旨在讨论DDR、新批准的靶向治疗以及转移性CRPC背景下的最新临床试验。
Zotero 插件